Clinical Trial Update: A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD). [Phase 4]

View source ↗

Summary

A 24-week Phase 4 trial in COPD evaluated safety and efficacy of Advair Diskus 250/50 mcg plus Spiriva HandiHaler versus Spiriva HandiHaler plus placebo Diskus;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ADVAIR DISKUS (fluticasone propionate and salmeterol)
• SPIRIVA HANDIHALER (TIOTROPIUM BROMIDE)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2010-12-10